Clinical Trial: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs ( SPECTRAL-1 )

U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07488923) titled 'A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs ( SPECTRAL-1 )' on March 13.

Brief Summary: This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer (SCLC ) Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Gastroenteropancreatic NEC (GEP NEC)...